Neuronal nicotinic acetylcholine receptor alpha-4 beta-2 and alpha-6 beta-2 subtypes (α4β2* and α6β2* nAChR)

The α4β2* and α6β2* nicotinic acetylcholine receptors (nAChRs) are the primary high-affinity heteromeric nicotinic receptors found in the mammalian central nervous system [1], [8]. These receptors function as pentameric ligand-gated ion channels that modulate the release of key neurotransmitters, including dopamine, GABA, and glutamate, thereby influencing reward pathways, cognitive processes, and motor coordination [3], [13]. The α4β2* subtype is widely distributed throughout the brain and is the principal mediator of nicotine's reinforcing effects, while the α6β2* subtype is more localized to dopaminergic terminals in the striatum and nucleus accumbens [1], [10]. Due to their central role in the mesolimbic dopamine system, these receptors are major therapeutic targets for smoking cessation and the treatment of nicotine addiction [6], [12]. Furthermore, their involvement in the nigrostriatal pathway and cognitive circuits makes them significant targets for neurodegenerative and psychiatric disorders, such as Parkinson's disease, Alzheimer's disease, and schizophrenia [1], [7]. Current pharmacological strategies involve the use of partial agonists, like varenicline, to provide moderate receptor stimulation while blocking the effects of exogenous nicotine, though achieving high subtype selectivity remains a challenge to minimize side effects like nausea [5], [11].

Other names

alpha4beta2 nicotinic receptoralpha6beta2 nicotinic receptornAChR alpha4beta2nAChR alpha6beta2High-affinity neuronal nicotinic acetylcholine receptorsCHRNA4-CHRNB2 receptorCHRNA6-CHRNB2 receptor

These receptors are pentameric ligand-gated ion channels that, upon binding of an agonist such as acetylcholine or nicotine, undergo a conformational change to open a cation-selective pore [3], [5]. This allows the influx of sodium and calcium ions, leading to neuronal depolarization and the subsequent release of various neurotransmitters, most notably dopamine in the mesolimbic and nigrostriatal pathways [1], [6]. Drugs targeting these receptors act as full agonists, partial agonists, or antagonists to modulate these signaling pathways, which are critical for reward, cognition, and motor control [10], [12].